According to filings with the U.S. Securities and Exchange Commission, Terremoto Biosciences is raised $108 Million in new Series C funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Terremoto Biosciences
Terremoto Biosciences is a clinical-stage biotechnology company creating highly targeted, small molecule medicines with unmatched selectivity, potency and efficacy designed to deliver superior therapeutic benefit to patients. Terremoto is a private company supported by world-class investors and is based in South San Francisco and San Diego, California.

To learn more, visit https://terremotobio.com/
Linkedin Page: https://www.linkedin.com/company/terremoto-biosciences/

Contact:
Charles Baum, Chief Executive Officer
https://www.linkedin.com/in/charlesbaum/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.